All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Cytokine-induced killer (CIK) cells are a heterogeneous population of polyclonal T cells that acquire phenotypic and cytotoxic properties of natural killer (NK) cells through the cultivation process, becoming so-called T-NK cells. CIK cells are capable of killing tumors in an unrestricted major histocompatibility complex (MHC) manner and can be genetically modified to express CARs. Taken together, the promising safety profile of patients in an allogeneic setting, MHC-independent cytotoxicity capability, and unique NK cell-like phenotype make CAR CIK cells a viable alternative for targeting cancer.
Our CAR CIK cells are engineeried by incorporation of second-generation CAR into PBMC-derived CIK cells using the non-viral Sleeping Beauty (SB) transposon or CAR lentivirus transduction technology. These CAR CIK cells are expected to exhibit robust antitumor activity in xenograft mouse models compared to unmodified CIK cells.
There are currently no customer reviews or questions for Anti-CD83 (XP5-1109) h(4-1BB-CD3ζ) CAR-CIK Cells (XS-0522-ZP1109). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION